Systemic immune-inflammation index as a potential biomarker for predicting acute pulmonary embolism: A systematic review

• Published in: Romanian Journal of Internal Medicine Vol. 62; no. 3; pp. 231 - 240
• Main Authors: Suwadi, Andrew, Tandarto, Kevin, Laksono, Sidhi
• Format: Journal Article
• Language: English
• Published: Germany Sciendo 01-09-2024
• Subjects: Acute Disease; Biomarkers - blood; Humans; immune marker; Inflammation; Predictive Value of Tests; Prognosis; pulmonary embolism; Pulmonary Embolism - blood; Pulmonary Embolism - diagnosis; Pulmonary Embolism - mortality; Sensitivity and Specificity; Severity of Illness Index; vascular diseases; Inflammation; Pulmonary Embolism; Prognosis; Vascular Diseases; Immune Marker
• ISSN: 2501-062X
• DOI: 10.2478/rjim-2024-0016

Acute pulmonary embolism (APE) is a life-threatening condition with a high mortality rate. The pathophysiology involves various complex processes. The systemic immune-inflammatory index (SII) is a well-known biomarker that reflects the intricate balance between pro-inflammatory and anti-inflammatory immune components. In this systematic review, we aim to determine the significance of SII as a potential biomarker for APE.
We utilized PubMed, ProQuest, EBSCOHost, and Google Scholar to search for articles. We assessed bias risk using the Newcastle Ottawa Scale (NOS). The outcomes we examined included in-hospital and long-term mortality, the severity of APE, and the sensitivity and specificity of the SII in predicting APE.
Four studies, involving 2,038 patients, were included for analysis. These studies discuss the use of SII in predicting APE severity, APE mortality, high-risk APE, and the occurrence of APE. SII demonstrates significant results in predicting each of these variables. Furthermore, each study establishes different SII cut-off values. Specifically, a cut-off of 1161 predicts massive APE events with a sensitivity of 91% and a specificity of 90%. A cut-off of >1235.35 differentiates high-risk APE with a sensitivity of 87.32% and a specificity of 68.85%. A cut-off of >1111x10
predicts overall mortality with a sensitivity of 72% and a specificity of 51%. Finally, a cut-off at 1839.91 predicts APE events with a sensitivity of 75.8% and a specificity of 61.9%.
The SII can be employed as a potential new biomarker to predict outcomes in APE patients, particularly the occurrence, severity, and mortality of APE.